Company Description
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Emrosi for the treatment of inflammatory lesions of rosacea, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis.
The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
| Country | United States |
| Founded | 2014 |
| IPO Date | Nov 12, 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 41 |
| CEO | Claude Maraoui |
Contact Details
Address: 9237 East Via de Ventura Boulevard, Suite 105 Scottsdale, Arizona 85258 United States | |
| Phone | 480 434 6670 |
| Website | journeymedicalcorp.com |
Stock Details
| Ticker Symbol | DERM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001867066 |
| CUSIP Number | 48115J109 |
| ISIN Number | US48115J1097 |
| Employer ID | 47-1879539 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Claude Maraoui | Founder, President, Chief Executive Officer and Director |
| Dr. Lindsay Allan Rosenwald | Executive Chairman |
| Joseph M. Benesch | Chief Financial Officer and Corporate Controller |
| Ramsey Alloush | Chief Operating Officer, General Counsel and Company Secretary |
| Robert Nevin | Chief Commercial Officer |
| Jaclyn Jaffe | Senior Director of Corporate Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 18, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 3, 2025 | 8-K | Current Report |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 26, 2025 | 8-K | Current Report |
| Mar 24, 2025 | 8-K | Current Report |
| Feb 5, 2025 | 8-K | Current Report |
| Nov 29, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |